CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 81 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.90 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $76,000 | -54.2% | 30,000 | -50.0% | 0.00% | -57.1% |
| Q2 2017 | $166,000 | +24.8% | 60,000 | -11.8% | 0.01% | +40.0% |
| Q1 2017 | $133,000 | +87.3% | 68,000 | 0.0% | 0.01% | +66.7% |
| Q4 2016 | $71,000 | -4.1% | 68,000 | 0.0% | 0.00% | -40.0% |
| Q3 2016 | $74,000 | +51.0% | 68,000 | -1.8% | 0.01% | +25.0% |
| Q2 2016 | $49,000 | -65.7% | 69,255 | -43.2% | 0.00% | -33.3% |
| Q1 2016 | $143,000 | -52.2% | 122,000 | 0.0% | 0.01% | -71.4% |
| Q4 2015 | $299,000 | -18.3% | 122,000 | 0.0% | 0.02% | +31.2% |
| Q3 2015 | $366,000 | -31.8% | 122,000 | -6.2% | 0.02% | -23.8% |
| Q2 2015 | $537,000 | -16.2% | 130,000 | -12.2% | 0.02% | -25.0% |
| Q1 2015 | $641,000 | +34.9% | 148,000 | -7.5% | 0.03% | +75.0% |
| Q4 2014 | $475,000 | -4.6% | 160,000 | +6.7% | 0.02% | +33.3% |
| Q3 2014 | $498,000 | -6.2% | 150,000 | -28.6% | 0.01% | 0.0% |
| Q2 2014 | $531,000 | +135.0% | 210,000 | +110.0% | 0.01% | +140.0% |
| Q1 2014 | $226,000 | – | 100,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,378,584 | $3,116,000 | 2.30% |
| TANAKA CAPITAL MANAGEMENT INC | 147,993 | $298,000 | 0.90% |
| SOPHROSYNE CAPITAL LLC | 282,500 | $638,000 | 0.56% |
| Ghost Tree Capital, LLC | 200,000 | $452,000 | 0.27% |
| Orbimed Advisors | 1,895,000 | $4,283,000 | 0.05% |
| Financial Architects, Inc | 30,000 | $68,000 | 0.04% |
| Cowen Prime Services LLC | 43,550 | $98,000 | 0.04% |
| Rotella Capital Management, Inc. | 12,300 | $28,000 | 0.03% |
| FEDERATED HERMES, INC. | 3,267,000 | $7,384,000 | 0.02% |
| Baker Brothers Advisors | 569,853 | $1,288,000 | 0.02% |